FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3044446585> ?p ?o ?g. }

• W3044446585 endingPage "189" @default.
• W3044446585 startingPage "177" @default.
• W3044446585 abstract "Protease inhibitors such as darunavir are an important therapeutic option in the anti-human immunodeficiency virus arsenal. Current dosage guidelines recommend using cobicistat- or ritonavir-boosted darunavir 800 mg every 24 h (q24h) in protease inhibitor-naive patients, or ritonavir-boosted darunavir 600 mg q12h in experienced patients. However, darunavir displays a large, poorly characterized, inter-individual pharmacokinetic variability. The objectives of this study were to investigate the pharmacokinetics of darunavir and to elucidate the sources of its inter-individual variability using population pharmacokinetic modeling. Then, to determine the appropriateness of current treatment guidelines and the feasibility of alternative dosing regimens in a representative cohort of adult patients using simulations. Sparse pharmacokinetic samples were collected in 127 patients with human immunodeficiency virus type 1 infection, then supplemented with rich sampling data from a subset of 12 individuals. Data were analyzed using the nonlinear mixed-effects modeling software NONMEM. The effect of reduced doses (600 mg q24h and 400 mg q24h) or reduced frequency of administration (800 mg q24h for 5 days followed by 2 days of treatment interruption) was simulated. Our model adequately described the pharmacokinetics of darunavir. Predictors of individual exposure were CYP3A5*3 and SLCO3A1 rs8027174 genotypes, sex, and alpha-1 acid glycoprotein level. No relationship was apparent between darunavir area under the curve and treatment efficacy or safety. For reduced dose regimens, darunavir concentrations remained above the protein binding-corrected EC50 in the majority of subjects. More stringent pharmacokinetic targets were not reached in a significant proportion of patients. These results add to the growing body of evidence that darunavir-based therapy could be simplified to reduce costs and toxicity, as well as to improve patient compliance. However, the heterogeneity in pharmacokinetic response should be considered when assessing whether individual patients could benefit from a particular regimen, for instance through the use of population pharmacokinetic models. ClinicalTrials.gov identifier: NCT03101644, date of registration: 5 April, 2017." @default.
• W3044446585 created "2020-07-29" @default.
• W3044446585 creator A5021675144 @default.
• W3044446585 creator A5034998415 @default.
• W3044446585 creator A5051216300 @default.
• W3044446585 creator A5052160158 @default.
• W3044446585 creator A5057687580 @default.
• W3044446585 creator A5080761370 @default.
• W3044446585 date "2020-07-22" @default.
• W3044446585 modified "2023-10-09" @default.
• W3044446585 title "Exploration of Reduced Doses and Short-Cycle Therapy for Darunavir/Cobicistat in Patients with HIV Using Population Pharmacokinetic Modeling and Simulations" @default.
• W3044446585 cites W1506412639 @default.
• W3044446585 cites W1517281160 @default.
• W3044446585 cites W1569413592 @default.
• W3044446585 cites W1965479467 @default.
• W3044446585 cites W1965922975 @default.
• W3044446585 cites W1982766717 @default.
• W3044446585 cites W1999521622 @default.
• W3044446585 cites W2009179549 @default.
• W3044446585 cites W2022017978 @default.
• W3044446585 cites W2035560231 @default.
• W3044446585 cites W2075052091 @default.
• W3044446585 cites W2085088518 @default.
• W3044446585 cites W2090157578 @default.
• W3044446585 cites W2096408832 @default.
• W3044446585 cites W2097697666 @default.
• W3044446585 cites W2103513664 @default.
• W3044446585 cites W2104161734 @default.
• W3044446585 cites W2104549677 @default.
• W3044446585 cites W2118245054 @default.
• W3044446585 cites W2121737909 @default.
• W3044446585 cites W2122443477 @default.
• W3044446585 cites W2139167304 @default.
• W3044446585 cites W2139660325 @default.
• W3044446585 cites W2152494705 @default.
• W3044446585 cites W2157791496 @default.
• W3044446585 cites W2160650845 @default.
• W3044446585 cites W2197249585 @default.
• W3044446585 cites W2294678755 @default.
• W3044446585 cites W2406931452 @default.
• W3044446585 cites W2414650564 @default.
• W3044446585 cites W2421199209 @default.
• W3044446585 cites W2486712327 @default.
• W3044446585 cites W2541346513 @default.
• W3044446585 cites W2621684574 @default.
• W3044446585 cites W2774685237 @default.
• W3044446585 cites W2791488041 @default.
• W3044446585 cites W2794399776 @default.
• W3044446585 cites W2802341256 @default.
• W3044446585 cites W2804978609 @default.
• W3044446585 cites W2807056588 @default.
• W3044446585 cites W2808178055 @default.
• W3044446585 cites W2902972357 @default.
• W3044446585 cites W2906967770 @default.
• W3044446585 cites W2912577871 @default.
• W3044446585 cites W2915372808 @default.
• W3044446585 cites W2921843808 @default.
• W3044446585 cites W2950950783 @default.
• W3044446585 cites W2991215552 @default.
• W3044446585 cites W2546277117 @default.
• W3044446585 doi "https://doi.org/10.1007/s40262-020-00920-z" @default.
• W3044446585 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7862523" @default.
• W3044446585 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32696441" @default.
• W3044446585 hasPublicationYear "2020" @default.
• W3044446585 type Work @default.
• W3044446585 sameAs 3044446585 @default.
• W3044446585 citedByCount "3" @default.
• W3044446585 countsByYear W30444465852020 @default.
• W3044446585 countsByYear W30444465852021 @default.
• W3044446585 crossrefType "journal-article" @default.
• W3044446585 hasAuthorship W3044446585A5021675144 @default.
• W3044446585 hasAuthorship W3044446585A5034998415 @default.
• W3044446585 hasAuthorship W3044446585A5051216300 @default.
• W3044446585 hasAuthorship W3044446585A5052160158 @default.
• W3044446585 hasAuthorship W3044446585A5057687580 @default.
• W3044446585 hasAuthorship W3044446585A5080761370 @default.
• W3044446585 hasBestOaLocation W30444465851 @default.
• W3044446585 hasConcept C112705442 @default.
• W3044446585 hasConcept C126322002 @default.
• W3044446585 hasConcept C142462285 @default.
• W3044446585 hasConcept C159047783 @default.
• W3044446585 hasConcept C2779182219 @default.
• W3044446585 hasConcept C2779298103 @default.
• W3044446585 hasConcept C2780524789 @default.
• W3044446585 hasConcept C2908647359 @default.
• W3044446585 hasConcept C2993143319 @default.
• W3044446585 hasConcept C3013748606 @default.
• W3044446585 hasConcept C3020755252 @default.
• W3044446585 hasConcept C500440147 @default.
• W3044446585 hasConcept C71924100 @default.
• W3044446585 hasConcept C98274493 @default.
• W3044446585 hasConcept C99454951 @default.
• W3044446585 hasConceptScore W3044446585C112705442 @default.
• W3044446585 hasConceptScore W3044446585C126322002 @default.
• W3044446585 hasConceptScore W3044446585C142462285 @default.
• W3044446585 hasConceptScore W3044446585C159047783 @default.
• W3044446585 hasConceptScore W3044446585C2779182219 @default.
• W3044446585 hasConceptScore W3044446585C2779298103 @default.

• next